600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Closed 04-29 15:00:00
46.18
+0.57
+1.25%
High
46.86
Low
45.53
Vol
34.28M
Open
45.60
D1 Closing
45.61
Amplitude
2.92%
Mkt Cap
294.58B
Tradable Cap
294.58B
Total Shares
6.38B
T/O
1.59B
T/O Rate
0.54%
Tradable Shares
6.38B
P/B
7.04
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk
Dow Jones · 03-15
Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk
Jiangsu Hengrui Pharma Buys Back Co Shares Worth 624.7 Mln Yuan
Reuters · 2023-11-17
Jiangsu Hengrui Pharma Buys Back Co Shares Worth 624.7 Mln Yuan
Load more
Introduction
Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。
Issue price:
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":46.18,"timestamp":1714374000000,"preClose":45.61,"halted":0,"volume":34279567,"delay":0,"changeRate":0.0125,"floatShares":6379000000,"shares":6379000000,"eps":0.6949,"marketStatus":"Closed","change":0.57,"latestTime":"04-29 15:00:00","open":45.6,"high":46.86,"low":45.53,"amount":1586000000,"amplitude":0.0292,"askPrice":46.19,"askSize":727,"bidPrice":46.18,"bidSize":331,"shortable":0,"etf":0,"ttmEps":0.6949,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1714440600000},"marketStatusCode":5,"adr":0,"adjPreClose":45.61,"symbolType":"stock","openAndCloseTimeList":[[1714354200000,1714361400000],[1714366800000,1714374000000]],"highLimit":50.17,"lowLimit":41.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"isCdr":false,"pbRate":7.04,"roa":"--","peRate":66.455605,"roe":"3.33%","epsLYR":0.68,"committee":0.111494,"marketValue":294582000000,"turnoverRate":0.0054,"status":0,"floatMarketCap":294582000000},"requestUrl":"/m/hq/s/600276/","defaultTab":"news","newsList":[{"id":"2419916365","title":"Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2419916365","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2419916365?lang=en_us&edition=fundamental","pubTime":"2024-03-15 13:49","pubTimestamp":1710481740,"startTime":"0","endTime":"0","summary":"0549 GMT - Jiangsu Hengrui Medicine is likely to report strong earnings growth in 4Q 2023 and into 2024, helped by revenue recognition and sales pick up, Nomura analysts Jialin Zhang and Yi Xiang say in a research note. They expect Hengrui's 4Q sales to have grown 14.3% on a low base and continued growth of innovative drugs. Its 4Q gross profit margin likely improved by 0.3 percentage points to 84.1% on economies of scale and an increase in the proportion of high-margin innovative drugs, the analysts say. They raise Hengrui's 2023 and 2024 net profit forecasts by 3.2% and 11.6%, respectively. They increase the stock's target to CNY51.12 from CNY49.24 and maintain a neutral call. Shares last at CNY46.79. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2384358025","title":"Jiangsu Hengrui Pharma Buys Back Co Shares Worth 624.7 Mln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2384358025","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2384358025?lang=en_us&edition=fundamental","pubTime":"2023-11-17 17:54","pubTimestamp":1700214880,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co Ltd <600276.SS>:Says As Of Nov 17, It Has Bought Back Co Shares Worth 624.7 Million Yuan ($86.52 Million).","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":0.0943},{"period":"1month","weight":-0.0065},{"period":"3month","weight":0.1318},{"period":"6month","weight":0.0046},{"period":"1year","weight":-0.0504},{"period":"ytd","weight":0.0084}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"14482股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0613},{"period":"6month","weight":0.0235},{"period":"1year","weight":-0.06},{"period":"ytd","weight":0.0382}],"survey":" 江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。","serverTime":1714392110967,"listedPrice":11.98,"stockholders":"440465人(较上一季度减少5.31%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}